Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
First Claim
Patent Images
1. A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
- (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by weight of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
0 Assignments
0 Petitions
Accused Products
Abstract
A novel pharmaceutical composition is disclosed. It comprises a sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose;
(b) 0.25-4.5% by wieght of hydroxypropyl cellulose;
(c) 1-90% by weight of a carboxyvinyl polymer.
-
Citations
26 Claims
-
1. A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
-
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer. - View Dependent Claims (2, 3, 4)
-
-
5. A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising:
-
(a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; (c) 3-75% by weight of a carboxyvinyl polymer. - View Dependent Claims (6)
-
-
7. A sustained release pharmaceutical carrier suitable for admixture with active ingredients and particularly adapted for preparation of compositions suitable for administration of active ingredients through the buccal pouch of the mouth which comprises:
-
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°
C.;(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°
C.; and(c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20°
C.;(d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20°
C.;(e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution. - View Dependent Claims (8, 9)
-
-
10. A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising:
-
(a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising:
-
(a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75% by weight of a carboxyvinyl polymer. - View Dependent Claims (20)
-
-
21. A sustained release pharmaceutical composition adapted for administration via the buccal pouch of the mouth which comprises a sustained release carrier and an active therapeutic agent, said carrier comprising:
-
(a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20°
C.;(b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20°
C.; and(c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20°
C.;(d) 0.5-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20°
C.;(e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution. - View Dependent Claims (22)
-
-
23. A method for producing a sustained zero-order time release of an active pharmaceutical agent in the gastro-intestinal tract comprising:
-
forming an ingestible tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent; ingesting the tablet; and allowing the tablet to transit the gastro-intestinal tract and to slowly dissolve by the action of gastro-intestinal fluids thereupon, whereby the weakly acidic carboxy vinyl polymer reacts to form salts under the alkaline conditions in the small intestine of the gatro-intestinal tract to thereby produce a coating of the active pharmaceutical agent on the small intestine of the gastro-intestinal tract, which coating remains in place and from which the pharmaceutically active agent is slowly absorbed through the mucosa of the small intestine into the blood stream over a sustained period of from twelve to twenty-four hours, which is in excess of the time taken by an undissolved remnant of the tablet to transit the gastro-intestinal tract. - View Dependent Claims (24)
-
-
25. A method for facilitating the sustained time-release and absorption of large molecules of a pharmaceutically active agent through the mucosa of the buccal pouch of the mouth comprising:
-
forming a buccal tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent having a molecule size larger than the normal permeability of the mucosa in the buccal pouch of the mouth, and a sweetening agent at least thirty times as sweet as sugar; placing the buccal tablet in the buccal pouch of the mouth; and allowing saliva in the buccal pouch of the mouth to slowly dissolve the tablet such that the sweetener contacts the mucosa lining the buccal pouch of the mouth and causes an increase in the permeability of the mucosa to allow the molecules of the pharmaceutically active agent to penetrate and be absorbed into the bloodstream over a sustained period. - View Dependent Claims (26)
-
Specification